EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cannabidiolic Acid Rescues Deficits in Hippocampal Long-Term Potentiation in Models of Alzheimer’s Disease: An Electrophysiological and Proteomic Analysis

Beatriz Gil, Mairéad Sullivan, Caitriona Scaife iD, Jeffrey C Glennon iD, Caroline Herron

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26104944 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Beatriz Gil und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Biomolecular and Biomedical Sciences, University College Dublin, Conway Institute, Dublin 4, Ireland. Hauptthemen laut MEDLINE: Alzheimer Disease, Long-Term Potentiation, Hippocampus, Neuroprotective Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 100 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Jazz Pharmaceuticals UK and University College Dublin, Jazz Pharmaceutics UK (formerly GW), University College Dublin.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In this study, we have examined the neuroprotective effects of cannabidiolic acid (CBDA) in models of Alzheimer’s disease (AD). We used in vitro electrophysiological recording in hippocampal slices and performed proteomic analysis of cortical tissue from APPswe/PS1dE9 (APP/PS1) mice. In wild-type (WT) slices from C57BL6 mice, acute treatment with CBDA (10 μM) did not alter levels of hippocampal long-term potentiation (LTP); however, it did reverse the attenuation of LTP produced by acute beta amyloid peptide (Aβ42). We also examined the effects of CBDA or vehicle in APP/PS1 mice and WT littermates over a 5-week period at 8 months. LTP levels recorded in slices from WT mice treated with CBDA at 1, 10, or 30 mg/kg (IP) or vehicle were similar. LTP was attenuated in slices from vehicle-treated APP/PS1 compared to vehicle-treated WT mice, while treatment of APP/PS1 mice with all doses of CBDA reversed the deficits in LTP. There was also a deficit in paired-pulse facilitation (PPF) in vehicle-treated APP/PS1 compared to WT, indicating altered synaptic function and transmitter release; this was reversed in slices from CBDA-treated APP/PS1 mice. Levels of cortical soluble Aβ42 were similar across CBDA- and vehicle-treated groups; however, the level of aggregated Aβ42 was decreased in the CBDA-treated group. Proteomic analysis of cortical tissue from APP/PS1 cortex compared to WT revealed alterations in protein expression, with pathway enrichment analyses suggesting implicated canonical pathways, including mitochondrial dysfunction, protein sorting, and synaptogenesis; all were significantly improved by CBDA treatment. These changes likely facilitate the improvement in synaptic transmission and LTP we observed following CBDA treatment in APP/PS1 mice. This research suggests that CBDA should be considered a novel therapy for AD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseLong-Term PotentiationHippocampusNeuroprotective AgentsAnimalsMiceProteomicsDisease Models, AnimalAmyloid beta-PeptidesMice, Inbred C57BLMice, TransgenicMaleAmyloid beta-Protein Precursor

Stichwörter der Autor:innen

APP/PS1Alzheimer’s diseaseCBDAelectrophysiologylong-term potentiationproteomicssynaptic plasticity

Substanzen

Amyloid beta-PeptidesNeuroprotective AgentsAmyloid beta-Protein Precursor

Autor:innen und Institutionen

  • School of Biomolecular and Biomedical Sciences, University College Dublin, Conway Institute, Dublin 4, Ireland.
  • School of Medicine and Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Conway Institute, Dublin 4, Ireland.
  • Conway Institute, University College, Dublin 4, Ireland.

ORCID-Profile: Caitriona Scaife, Jeffrey C Glennon

Förderung

  • Jazz Pharmaceuticals UK and University College Dublin
  • Jazz Pharmaceutics UK (formerly GW)
  • University College Dublin

Zitieren

APA

Gil, B., Sullivan, M., Scaife, C., Glennon, J. C., & Herron, C. (2025). Cannabidiolic Acid Rescues Deficits in Hippocampal Long-Term Potentiation in Models of Alzheimer’s Disease: An Electrophysiological and Proteomic Analysis. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26104944

Vancouver

Gil B, Sullivan M, Scaife C, Glennon JC, Herron C. Cannabidiolic Acid Rescues Deficits in Hippocampal Long-Term Potentiation in Models of Alzheimer’s Disease: An Electrophysiological and Proteomic Analysis. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26104944

BibTeX
@article{Gil2025,
  author = {Gil, Beatriz and Sullivan, Mairéad and Scaife, Caitriona and Glennon, Jeffrey C and Herron, Caroline},
  title = {Cannabidiolic Acid Rescues Deficits in Hippocampal Long-Term Potentiation in Models of Alzheimer’s Disease: An Electrophysiological and Proteomic Analysis},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26104944}
}
Kostenlos starten →